## Warner Bros. Discovery Shareholders Reject David Zaslav's $886 Million Golden Parachute Linked to Paramount Merger—But Vote Is Non-Binding
Warner Bros. Discovery shareholders voted down a massive executive payout for CEO David Zaslav tied to the pending Paramount merger, even as they approved the deal itself during a special virtual meeting Thursday morning. The proposed golden parachute could have delivered Zaslav up to $886 million if the merger closes, making it one of the largest such packages in media industry history. The precise vote tally was not disclosed following the brief online session.

The outcome exposes a sharp disconnect between shareholder sentiment and corporate governance mechanics. While investors signaled clear opposition to the windfall, the non-binding nature of the vote means the payout could still proceed regardless of the outcome. The merger with Paramount, valued at approximately $26 billion including debt, moves forward under Zaslav's leadership despite the internal friction over his compensation. The deal would combine three major studios—Paramount, Warner Bros., and Discovery—into a formidable streaming and theatrical force.

The rejected package drew criticism from corporate governance advocates who argued the payout was disproportionate and poorly timed, coming as the combined company would face substantial integration costs and competitive pressure. WBD stock has underperformed since the 2022 merger that created the current entity. The vote puts pressure on the board to reconsider compensation structures ahead of the merger closing, though directors are not obligated to act on the shareholder directive. Regulators, including the FTC, continue to review the Paramount deal, with final approval remaining uncertain.
---
- **Source**: Deadline
- **Sector**: The Vault
- **Tags**: Warner Bros. Discovery, David Zaslav, Paramount merger, golden parachute, executive compensation
- **Credibility**: unverified
- **Published**: 2026-04-24 00:24:06
- **ID**: 76570
- **URL**: https://whisperx.ai/en/intel/76570